Moran Wealth Management LLC Invests $2.46 Million in DexCom, Inc. $DXCM

Key Points

• Moran Wealth Management LLC invested approximately $2.46 million in DexCom, Inc., acquiring 28,229 shares of the medical device company's stock in the second quarter.
• Recent earnings reported a net margin of 13.29% and a revenue of $1.16 billion, an increase of 15.2% year-over-year, surpassing analyst estimates.
• Institutional investors currently own 97.75% of DexCom's stock, indicating strong institutional interest in the company.

Moran Wealth Management LLC acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 28,229 shares of the medical device company's stock, valued at approximately $2,464,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Brighton Jones LLC boosted its holdings in shares of DexCom by 257.7% during the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company's stock valued at $1,290,000 after acquiring an additional 11,946 shares during the period. Farther Finance Advisors LLC lifted its position in DexCom by 29.3% in the 1st quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company's stock valued at $209,000 after purchasing an additional 702 shares during the last quarter. Dynamic Advisor Solutions LLC boosted its stake in DexCom by 34.2% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 5,235 shares of the medical device company's stock valued at $357,000 after purchasing an additional 1,333 shares during the period. Janney Montgomery Scott LLC grew its position in DexCom by 2.5% in the 1st quarter. Janney Montgomery Scott LLC now owns 238,424 shares of the medical device company's stock worth $16,282,000 after purchasing an additional 5,881 shares during the last quarter. Finally, Sagespring Wealth Partners LLC grew its position in DexCom by 96.1% in the 1st quarter. Sagespring Wealth Partners LLC now owns 10,552 shares of the medical device company's stock worth $721,000 after purchasing an additional 5,172 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

DexCom Price Performance

NASDAQ:DXCM opened at $65.41 on Thursday. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The business's 50-day moving average price is $73.79 and its 200 day moving average price is $77.54. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $93.25. The firm has a market cap of $25.65 billion, a P/E ratio of 45.42, a PEG ratio of 1.39 and a beta of 1.47.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same quarter last year, the firm posted $0.43 EPS. The business's revenue for the quarter was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on DXCM. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of DexCom in a report on Wednesday, October 8th. Citigroup cut their target price on DexCom from $105.00 to $85.00 and set a "buy" rating on the stock in a research note on Tuesday, October 7th. Piper Sandler increased their price target on DexCom from $90.00 to $100.00 and gave the stock an "overweight" rating in a research note on Thursday, July 31st. Raymond James Financial raised their price target on DexCom from $99.00 to $102.00 and gave the company a "strong-buy" rating in a report on Thursday, July 31st. Finally, Mizuho upped their price objective on shares of DexCom from $95.00 to $100.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat, DexCom presently has a consensus rating of "Moderate Buy" and an average target price of $97.00.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Sadie Stern sold 1,466 shares of the company's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total value of $117,280.00. Following the transaction, the executive vice president owned 105,223 shares of the company's stock, valued at approximately $8,417,840. This represents a 1.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael Jon Brown sold 500 shares of the firm's stock in a transaction on Friday, August 15th. The stock was sold at an average price of $80.29, for a total value of $40,145.00. Following the sale, the executive vice president directly owned 94,102 shares of the company's stock, valued at approximately $7,555,449.58. This represents a 0.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 6,849 shares of company stock worth $564,733. 0.32% of the stock is owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.